Abstract
Peripheral serum levels of dehydroepiandrosterone sulfate (DHAS), dehydroepiandrosterone (DHA), androstenedione (A4) and testosterone (T) were measured in two groups of premenopausal women with fibrocystic breast disease, given 200 and 400 mg of danazol a day respectively for 6 months. During treatment, DHAS levels increased and DHA, DHA/DHAS ratio, A4, and T decreased. A tendency towards dose dependency was observed. The changes in DHAS, DHA and DHA/DHAS ratio were interpreted as resulting from inhibition of liver sulfatase activity by danazol. The decreased A4 and T levels probably reflect a suppression of ovarian steroidogenesis due to enzyme inhibition by danazol, and for the latter steroid also and increased metabolism due to interaction of the drug with sex hormone-binding globulin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Acta obstetricia et gynecologica Scandinavica. Supplement
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
